Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
about
Structural Basis of Targeting the Exportin CRM1 in CancerSerine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer.NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.Apoptosis and associated phenomena as a determinants of the efficacy of photodynamic therapy.Identification and characterization of tyrosine kinases in anole lizard indicate the conserved tyrosine kinase repertoire in vertebrates.Breakpoint Cluster Region-Mediated Inflammation Is Dependent on Casein Kinase II.Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancerLoss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activitiesAdvances in studies of tyrosine kinase inhibitors and their acquired resistance.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study.Genome-Wide Identification and Characterization of Tyrosine Kinases in the Silkworm, Bombyx mori.
P2860
Q26781513-4AD64A06-A41F-45EF-AA68-4D11E08C67A9Q35496844-CEDA230E-D8BB-4D50-A64D-7EA49E643966Q35588883-ABBFC7FD-5238-4780-9B2C-598EA9C3F19AQ35872003-64BDD33E-09EA-4751-8629-EE80B40780C2Q35930811-4D065F26-BEC5-4FF8-BE71-1F5C37FF40A3Q36310219-28619D85-4C3C-4E61-A690-605181F855A8Q36483279-47D1EA48-5BD7-4C20-BB3C-DB28C9D8DD84Q37701501-D560DB39-0FE0-4774-9CF2-446F47DCCDB3Q38307797-589BF875-B48B-47D6-9C71-D4D1C59F7E80Q38618837-7B6CF6AA-7434-4265-AD2D-123315BB882CQ38746234-4C793159-E556-476E-86DB-4B30187F1002Q38826405-6FA346C9-DABF-4A3C-AEB4-7E1EF97C6DDEQ38868595-CD57AC06-8D8A-40A6-8635-5AE360841B0DQ41076612-FAE35A87-A3E5-4F7D-A75B-49A168AC37FDQ41786014-A89A42B4-6327-4678-8331-AFD57BC1DCA8Q49887903-71B072B0-8D78-4238-906B-3A81DCEE0330Q49888021-01CEC19E-309B-46D7-B49B-D844652FBA28Q51237587-3B24964C-DE50-4DDE-A1D7-329DB2528A47Q54120207-2BCC925A-32DF-46C9-9567-8B05BAF05773
P2860
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@ast
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@en
type
label
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@ast
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@en
prefLabel
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@ast
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@en
P2860
P356
P1476
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
@en
P2093
Owen N Witte
P2860
P304
P356
10.1128/MCB.01592-13
P407
P577
2014-02-24T00:00:00Z